“The present problem has uncovered some structural weaknesses while in the EU’s medicines source chain and also a substantial dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides mentioned. She advisable that supply chain concerns be resolved in an EU pharmaceutical technique predicted to generally be released by th